Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.

BACKGROUND

Standard-of-care treatment for patients with newly diagnosed multiple myeloma is bortezomib-based induction followed by high-dose melphalan and autologous haematopoietic stem-cell transplantation (HSCT) and lenalidomide maintenance. We aimed to evaluate whether an immunomodulatory-free carfilzomib-based induction, consolidation, and maintenance protocol without autologous HSCT was non-inferior to the same induction regimen followed by autologous HSCT and maintenance.

METHODS

CARDAMON is a randomised, open-label, phase 2 trial in 19 hospitals in England and Wales, UK. Newly diagnosed, transplantation-eligible patients with multiple myeloma aged 18 years or older with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 received four 28-day cycles of carfilzomib (56 mg/m

FINDINGS

Between June 16, 2015, and July 8, 2019, 281 patients were enrolled, with 218 proceeding to randomisation (109 assigned to the KCd consolidation group [99 of whom completed consolidation] and 109 to the HSCT group [104 of whom underwent transplantation]). A further seven patients withdrew before initiation of carfilzomib maintenance (two in the KCd consolidation group vs five in the HSCT group). Median age was 59 years (IQR 52 to 64); 166 (59%) of 281 patients were male and 115 (41%) were female. 152 (71%) of 214 patients with known ethnicity were White, 37 (17%) were Black, 18 (8%) were Asian, 5 (2%) identified as Mixed, and 2 (1%) identified as other. Median follow-up from randomisation was 40·2 months (IQR 32·7 to 51·8). After induction, 162 (57·7%; 95% CI 51·6 to 63·5) of 281 patients had at least a very good partial response. The 2-year progression-free survival was 75% (95% CI 65 to 82) in the HSCT group versus 68% (95% CI 58 to 76) in the KCd group (difference -7·2%, 70% CI -11·1 to -2·8), exceeding the non-inferiority margin. The most common grade 3-4 events during KCd induction and consolidation were lymphocytopenia (72 [26%] of 278 patients who started induction; 15 [14%] of 109 patients who started consolidation) and infection (50 [18%] of 278 for induction; 15 [14%] of 109 for consolidation), and during carfilzomib maintenance were hypertension (20 [21%] of 97 patients in the KCd consolidation group vs 23 [23%] of 99 patients in the HSCT group) and infection (16 [16%] of 97 patients vs 25 [25%] of 99). Treatment-related serious adverse events at any point during the trial were reported in 109 (39%) of 278 patients who started induction, with infections (80 [29%]) being the most common. Treatment-emergent deaths were reported in five (2%) of 278 patients during induction (three from infection, one from cardiac event, and one from renal failure) and one of 99 patients during maintenance after autologous HSCT (oesophageal carcinoma).

INTERPRETATION

KCd did not meet the criteria for non-inferiority compared with autologous HSCT, but the marginal difference in progression-free survival suggests that further studies are warranted to explore deferred autologous HSCT in some subgroups, such as individuals who are MRD negative after induction.

FUNDING

Cancer Research UK and Amgen.

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests KY receives honoraria from GlaxoSmithKline, Takeda, Janssen, Amgen, and Sanofi; and research funding from Janssen, Bristol Myers Squibb, and Autolus. KR receives honoraria from Karyopharm, Pfizer Oncology, Celgene, Takeda, Janssen, Amgen, Adaptive Biotech, Oncopeptides, GlaxoSmithKline, and Sanofi; is a member of an advisory committee for Karyopharm, Pfizer Oncology, Celgene, Takeda, Janssen, Amgen, Adaptive Biotech, Oncopeptides, GlaxoSmithKline, and Sanofi; receives fees for travel from Janssen, Amgen, Takeda, and Bristol Myers Squibb; receives fees for conference registration from Janssen, Amgen, Takeda, Bristol Myers Squibb (Celgene), Karyopharm, GlaxoSmithKline, Pfizer, Sanofi, and Abbvie; and receives research funding from Bristol Myers Squibb, Janssen, Takeda, Amgen, and GlaxoSmithKline. MS receives consultancy fees from Celgene, Sanofi, and EUSA Pharma. LC-H receives research funding from Bristol-Myers Squibb. RGO receives honoraria from Janssen, Beigene, and AstraZeneca, and is a member of an advisory committee for Janssen and Beigene. RP receives consultancy fees from GlaxoSmithKline, Abbvie, Takeda, Janssen, and Celgene; honoraria from GlaxoSmithKline, AbbVie, Bristol Myers Squibb, Janssen, Oncopeptides, Amgen, and Takeda; research funding from GlaxoSmithKline; fees for travel, fees for accommodation, and expenses from Takeda; and fees for travel from Janssen and Bristol Myers Squibb. The haematology team at the Cancer Research UK and University College London Cancer Trials Centre (LC-H, GP, RJ, TD, WW, and SK) has received funding (which in part pays staff salary) to sponsor and coordinate clinical trials from Amgen, Celgene, Merck Sharp and Dohme, Janssen, Pfizer, and Millennium Pharmaceuticals. All other authors declare no competing interests.